Popular
BLCO · Health care · Canada

Bausch + Lomb

Makes contact lenses, eye drops and tools for eye surgery.

Company Health

23
/100
Fragile
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $7 of every $100 in sales.
Is it growing?
19 of 25 · Good
Sales grew about 11% a year over the last 3 years.
Can it handle what it owes?
0 of 25 · Poor
It would take about 25 years of the cash its business brings in to pay off everything it owes.
Does it bring in spare cash?
4 of 25 · Poor
It spent more cash than it brought in: $1 of every $100 in sales.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Bausch + Lomb’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $3.41 billion in 2020 to $5.10 billion in 2025, and it made a profit in 2 of the 6 years.
2025
Sales
$5.10 billion
Loss
$360 million

Spare cash each year

It had cash to spare in 3 of the 6 years, but in 2025 it spent $66.0 million more than it brought in.
2025
Cash shortfall
$66.0 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $14.0 billion, including $383 million in cash, and owed $7.50 billion.

Key facts

From its yearly report for 2025.
Sales
$5.10 billion
Loss
$360 million
Cash shortfall
$66.0 million
Cash in the bank
$383 million
Everything it owes
$7.50 billion
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 18, 2026
Figures from Bausch + Lomb’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy